Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate

Journal of Controlled Release

Volumn 47, Issue 3, 1997, Pages 293-304

  Dosio, Franco ^a   Brusa, Paola ^a   Crosasso, Paola ^a   Arpicco, Silvia ^a   Cattel, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Albumin; Antitumoral agent; Macromolecular drug conjugate; Paclitaxel

Indexed keywords

HUMAN SERUM ALBUMIN; PACLITAXEL; PACLITAXEL DERIVATIVE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG SOLUBILITY; DRUG STABILITY; FEMALE; GEL ELECTROPHORESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INTERNALIZATION; INTRAVENOUS DRUG ADMINISTRATION; ISOELECTRIC FOCUSING; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0030947239     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)01656-8     Document Type: Article

References (49)

1. E.K. Rowinsky and R.C. Donehower, Paclitaxel (Taxol). N. Engl. J. Med. 332 (1995) 1004-1014.
2. C.M. Spencer and D. Faulds, Paclitaxel. Drugs 48 (1994) 794-847.
3. J.J. Master, J.T. Link, L.B. Snyder, W.B. Young and S.J. Danishefsky, A total synthesis of taxol. Angew. Chem. (Int. Edn.) 34 (1995) 1723-1726.
4. R.A. Holton, H. Kim, C. Somoza, F. Linag, J. Biediger et al., First total synthesis of taxol. 2. Completion of the C and D rings. J. Am. Chem. Soc. 116 (1994) 1599-1600.
5. K.C. Nicolau, Z. Yang, J.J. Liu, H. Ueno, P.G. Nauternet and R.K. Guy, Total synthesis of taxol. Nature 367 (1994) 630-634.
6. M.-L. Fjallskog, L. Frii and J. Bergh, Is cremophor, solvent for paclitaxel, cytotoxic? Lancet 342 (1993) 876.
7. E.K. Rowinsky, E.A. Eisenhauer, V. Chaudry, S.G. Arbuck and R.C. Donehower, Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. 20 (1993) 1-15.
8. R.B. Weiss, R.C. Donehower, P.H. Wiernik, T. Ohnuma, R.L. Gralla, D. Trump, J.R. Baker, D.A. VanEcho, D.D. VonHoff and B. Leyland-Jones, Hypersensitivity reactions from taxol. J. Clin. Oncol. 8 (1990) 1263-1268.
9. J. Riondel, M. Jacrot, H. Fessi and F. Puisieux, Effects of free and liposome - encapsulated taxol on two brain tumors xenografted in nude mice. In vivo. 6 (1992) 23-28.
10. A. Sharma, E. Mayhew and R.M. Straubingen, Antitumoral effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res. 53 (1993) 5877-5881.
11. A. Sharma, S.V. Balasubramianian and R.M. Straubingen, Pharmaceutical and physical properties of paclitaxel (taxol) complexes with cyclodextrins. J. Pharm. Sci. 84 (1995) 1223-1230.
12. T. Cserhati, E. Forgacs and J. Hollo, Interaction of taxol and other anticancer drugs with α-cyclodextrin. J. Pharm. Biomed. Anal. 13 (1995) 533-541.
13. H. Alkan-Onyuksel, S. Ramakrishnan, H.-B. Chai and J.M. Pezzuto, A mixed micellar formulation suitable for the parenteral administration of taxol. Pharm. Res. 11 (1994) 206-212.
14. R.B. Greenwald, C.W. Gilbert, A. Pendri, C.D. Conover, J. Xia and A. Martinez, Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem. 39 (1996) 424-431.
15. H. Maeda, L.W. Seymour and Y. Miyamoto, Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconj. Chem. 3 (1992) 351-361.
16. R.M. Reilly, J. Sandhu, T.M. Alvarez-Diez, S. Gallinger, J. Kirsh and H. Stern, Problems of delivery of monoclonal antibodies. Clin. Pharmacokinet. 28 (1995) 126-142.
17. Z. Brich, S. Ravel, T. Kissel, J. Fritsch and A. Schoffmann, Preparation and characterization of a water soluble dextran immunoconjugate of doxorubicin and the monoclonal antibody (ABL 364). J. Control. Release 19 (1992) 245-258.
18. B.M. Mueller, R.A. Reisfeld, M.H. Silveira, J.D. Duncan and W.A. Wrasidlo, Pre-clinical therapy of human melanoma with morpholino-doxorubicin conjugated to a monoclonal antibody directed against an integrin on melanoma cells. Antibody Immunoconj. Radiopharm. 4 (1991) 99-104.
19. G.P. Sivam, P.J. Martin, R.A. Reisfeld and B.M. Mueller, Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneuos metastatic human melanoma. Cancer Res. 55 (1995) 2352-2355.
20. Y. Takakura, A. Takagi, M. Hashida and H. Sezaki, Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm. Res. 4 (1987) 293-300.
21. R.K. Jain, Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50 (1990) 814S-819S.
22. A.B. Malik and A. Siflinger-Birnboim, Vascular endothelial barrier function and its regulation. In: K.L. Audus and T.J. Raub (Eds.), Biological barriers to protein delivery. Plenum Press, N.Y., 1993, pp. 231-245.
23. R. Duncan, Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs 3 (1992) 175-210.
24. R. Duncan and F. Spreafico, Polymer conjugates, pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 27 (1994) 290-306.
25. K. Ohkwada, T. Hatano, K. Yamada, K. Joh, Y. Tsukada and M. Matsuda, Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistence in rat hepatoma. Cancer Res. 53 (1993) 4238-4242.
26. L. Fiume, C. Busi, A. Mattioli and G. Spinosa, Targeting of antiviral drugs bound to protein carriers. CRC Crit. Rev. Therap. Drug Carrier Syst. 4 (1988) 265-284.
27. Y. Matsumura and H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res. 46 (1986) 6387-6392.
28. J.C. Cerrottini and H. Isliker, Transport of cytostatic agents by plasma proteins. Penetration of serum albumin into tumor cells. Eur. J. Cancer. 3 (1967) 111-124.
29. B.C.F. Chu and J.M. Whiteley, High molecular weight derivatives of methotrexate as chemotherapeutic agents. Mol. Pharmacol. 13 (1977) 80-88.
30. U.K. Laemmli, Cleavage of structural proteins during the assembly of the head of batteriophage T4. Nature, 227 (1970) 680-685.
31. A.F.S.A. Habeeb, Preparation of enzimatically active, water insoluble derivatives of trypsin. Arch. Biochem. Biophys. 119 (1967) 264-268.
32. A.F.S.A. Habeeb, Determination of free amino groups in proteins by trinitrobenzene sulfonic acid. Anal. Biochem. 14 (1966) 328-336.
33. J.B. Lloyd and R.T. Dean, The lysosome and its membrane. Biochem Soc. Transact. 12 (1984) 899-912.
34. T. Kooistra, P.C. Millard and J.B. Lloyd, Role of thiols in degradation of proteins by cathepsins. Biochem. J. 204 (1982) 471-477.
35. A. Sharma, W.D. Conway and R.M. Straubinger, Reverse-phase high-performance liquid chromatographic determination of taxol in mouse plasma. J Chrom. B. 655 (1994) 315-319.
36. J. Leslie, J.M. Kujawa, N. Eddington, M. Egorin and J. Eiseman, Stability problems with taxol in mouse plasma during analysis by liquid chromatography. J. Pharm. Biomed. Anal. 11 (1993) 1349-1352.
37. J. Kopecek and R. Duncan, Targetable polymeric prodrugs. J. Control. Release 6 (1987) 315-327.
38. N. Mongelli, E. Pesenti, A. Suarato and G. Biasioli, Polymer-bound paclitaxel derivatives. US Patent 5,362,831, 1994.
39. J. Kopecek, The potential of water soluble polymeric carriers in targeted and site specific drug delivery. J. Control. Release 11 (1990) 279-290.
40. P.H. Wiernik, E.L. Scwartz, J.J. Strauman, J.P. Dutcher, R.B. Lipton and E. Paietta, Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 47 (1987) 2486-2493.
41. E.J. Yoon, H.W. Chang, M.G. Lee, H. Lee, M.K. Park and C.K. Kim, Pharmacokinetics of methotrexate after iv infusion of methotrexate-rabbit serum albumin conjugate to rabbits. Int. J. Pharm. 67 (1991) 177-182.
42. T. Tanaka, Y. Kaneo and S. Iguchi, Properties of mitomycin C-albumin conjugates in vitro and in vivo. Bioconj. Chem. 2 (1991) 261-269.
43. Y. Kaneo, T. Tanaka and S. Iguchi, Preparation and properties of mitomycin C-albumin conjugate. Chem. Pharm. Bull. 38 (1990) 2614-2616.
44. L. Fiume, B. Bassi, C. Busi, A. Mattioli and G. Spinosa, Drug targeting in antiviral chemoterapy. Biochem. Pharmacol. 35 (1986) 967-972.
45. R.S. Greenfield, P.D. Senter, A.T. Daues, K.A. Fitzgerald, S. Gawlak, W. Manger and G.R. Braslawsy, In vitro evaluation of immunoconjugates prepared by linking mitomyvin C to monoclonal antibodies via polyglutamic acid carriers. Antibody, Immunoconj. Radiopahrm. 2 (1989) 201-209.
46. S. Li, X. Zhang, T. Qiao, X. Chen, S. Zhang and L. Chen, Enhanced antitumor activity of daunomycin conjugated with antigastric cancer monoclonal antibody MGb2. Oncol. Res. 4 (1992) 447-453.
47. R.V.J. Chari, K.A. Jackel, L.A. Bourret, S.M. Derr, B.M. Tadayoni, K.M. Mattocks, S.A. Shah, C. Liu, W.A. Blattler and V.S. Goldmacher, Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res. 55 (1995) 4079-4084.
48. E.K. Rowinsky, R.C. Donehower, R.J. Jones and R.W. Tucker, Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 48 (1988) 4093-4100.
49. S.G. Arbuck, G. Canetta, N. Onetto and M.C. Christian, Current dosage and schedule issues in the development of paclitaxel (Taxol). Semin. Oncol. 20(3), (1993) Suppl. 3, 31-39.